959122-10-2

Usage

InChI:InChI=1/C27H26N2O4/c1-33-26(31)24-9-5-8-23(24)25(30)20-12-10-18(11-13-20)19-14-16-22(17-15-19)29-27(32)28-21-6-3-2-4-7-21/h2-4,6-7,10-17,23-24H,5,8-9H2,1H3,(H2,28,29,32)/t23-,24-/m1/s1

Upstream product

• 791594-14-4 methyl (1R,2R)-2-(4-bromobenzoyl)cyclopentanecarboxylate 
• 791594-11-1 methyl cis-2-(4-bromobenzoyl)cyclopentanecarboxylate 
• 1019115-10-6 trans-(+/-)-2-(4-bromobenzoyl)cyclopentanecarboxylic acid 
• 171364-83-3 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)nitrobenzene 
• 586-75-4 4-chlorobenzoyl chloride 
• 1655-07-8 ethyl 2-oxocyclohexane carboxylate 
• 108-94-1 cyclohexanone 
• 103-71-9 phenyl isocyanate 
• 1214270-80-0 2-bromo-6-(4-bromobenzoyl)cyclohexanone 
• 791594-13-3 trans-(1R,2R)-2-(4-bromobenzoyl)cyclopentanecarboxylic acid 
• 959123-13-8 methyl (1R,2R)-2-[(4'-amino-1,1'-biphenyl-4-yl)carbonyl]cyclopentanecarboxylate 

Relevant academic research and scientific papers

Process development of a diacyl glycerolacyltransferase-1 inhibitor

A synthesis of a selective diacyl glycerolacyltransferase-1 (DGAT-1) inhibitor, 1, is described. The synthesis illustrates a diketone Favorskii reaction on 9 in place of the more common ketoester variant for generation of the dicarboxycyclopentane core, t

Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme

The present invention relates to compounds of formula (I). wherein R1, R2, R3, R4, R5, R6, m, n, p and q are defined herein Pharmaceutical compositions and methods for treating DGAT-1 relat

Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor

A highly potent and selective DGAT-1 inhibitor was identified and used in rodent models of obesity and postprandial chylomicron excursion to validate DGAT-1 inhibition as a novel approach for the treatment of metabolic diseases. Specifically, compound 4a conferred weight loss and a reduction in liver triglycerides when dosed chronically in DIO mice and depleted serum triglycerides following a lipid challenge in a dose-dependent manner, thus, reproducing major phenotypical characteristics of DGAT-1-/- mice.

INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME

The present invention relates to compounds of formula (I) wherein R1, R3, X, Q, Z, A, D, m, and n are defined herein. Pharmaceutical compositions and methods for treating DGAT-1 related diseases or conditions are also disclosed.